Targovax reports promising disease-free su...Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer. more ➔
EU set to speed up switch to bioeconomy by...Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased … more ➔
Bacterial antigen mimicry drives MST cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS). more ➔
Affimed halts trial after patient death an...Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I … more ➔
Sitryx Therapeutics bags $30m in Series A...Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and … more ➔
Orchard plans to raise US$172m in ADSBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen … more ➔
Sphingotec raises €20m in growth equity...Diagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington … more ➔
Sanofi and Evotec launch drug discovery PP...Evotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas. more ➔
Roche providing improved anti-Her2 bispeci...Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds. more ➔
Forbion closes Life Sciences VC Fund at ...Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m. more ➔
